Traws Pharma, Inc. — Director's Dealing 2016

Aug 11, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Onconova Therapeutics, Inc. (ONTX)
CIK: 0001130598
Period of Report: 2016-07-26

Reporting Person: Kumar Ramesh (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-07-29	Common Stock	X	50765	$4.10	Acquired	78417	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-07-26	Subscription Right (right to buy)	$4.10	X	41475	Disposed	2016-07-26	See footnote (41475)	Direct
2016-07-29	Warrants (right to buy)	$4.92	X	38071	Acquired	2021-07-27	Common Stock (38071)	Direct

Footnotes

F1: The common stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by the Issuer to all holders of the Issuer's common stock. Each holder received 1.5 subscription rights per share of stock owned, and each right allowed the recipient to purchase one unit, consisting of one share of common stock and 0.75 of a warrant to purchase one share of common stock. The subscription price per unit was $4.10. Holders of the subscription rights, including the Reporting Person, also had an overallotment privilege to subscribe for additional units not purchased by other holders, subject to allocation. The allocation of the overallotment privilege to persons who hold their securities through a broker was completed on August 1, 2016.

F2: Each warrant entitles the holder to purchase one share of common stock at an exercise price of $4.92 from the date of issuance through July 27, 2021.

F3: 37,510 shares are held by the Ramesh Kumar 2012 Trust, of which the reporting person is a trustee.